Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5608_Библиотеки_им_академика_М_И_Перельмана.pdf
130
24. Zhang L, Inniss MC, Han S, Moffat M, Jones H, Zhang B, Cox WL, Rance JR, Young RJ
(2015) Recombinase-mediated cassette exchange (RMCE) for monoclonal antibody expression in the commercially relevant CHOK1SV cell line. Biotechnol Prog 31:1645–1656.
https://doi.org/10.1002/btpr.2175
25. Inniss MC, Bandara K, Jusiak B, Lu TK, Weiss R, Wroblewska L, Zhang L (2017) A novel
Bxb1 integrase RMCE system for high delity site-specic integration of mAb expression
cassette in CHO cells. Biotechnol Bioeng 114:1837–1846. https://doi.org/10.1002/bit.26268
26. Schlatter S, Stanseld SH, Dinnis DM, Racher AJ, Birch JR, James DC (2005) On the optimal
ratio of heavy to light chain genes for efcient recombinant antibody production by CHO cells.
Biotechnol Prog 21:122–133. https://doi.org/10.1021/bp049780w
27. Gonz Lez R, Andrews BA, Asenjo JA (2002) Kinetic model of BiP- and PDI-mediated protein
folding and assembly. J Theor Biol 214:529–537. https://doi.org/10.1006/jtbi.2001.2478
28. O’Callaghan PM, McLeod J, Pybus LP, Lovelady CS, Wilkinson SJ, Racher AJ, Porter A,
James DC (2010) Cell line-specic control of recombinant monoclonal antibody production
by CHO cells. Biotechnol Bioeng 106:938–951. https://doi.org/10.1002/bit.22769
29. Baumal R, Scharff MD (1973) Synthesis, assembly and secretion of gamma-globulin by
mouse myeloma cells. V. Balanced and unbalanced synthesis of heavy and light chains by
IgG-producing tumors and cell lines. J Immunol 111:448–456
30. Ho SC, Koh EY, van Beers M, Mueller M, Wan C, Teo G, Song Z, Tong YW, Bardor M,
Yang Y (2013) Control of IgG LC:HC ratio in stably transfected CHO cells and study of the
impact on expression, aggregation, glycosylation and conformational stability. J Biotechnol
165:157–166. https://doi.org/10.1016/j.jbiotec.2013.03.019
31. Ghose S, Allen M, Hubbard B, Brooks C, Cramer SM (2005) Antibody variable region interactions with Protein A: implications for the development of generic purication processes.
Biotechnol Bioeng 92:665–673. https://doi.org/10.1002/bit.20729
32. Sasso EH, Silverman GJ, Mannik M (1991) Human IgA and IgG F(ab’)2 that bind to staphylococcal protein A belong to the VHIII subgroup. J Immunol 147:1877–1883
33. Hiller GW, Ovalle AM, Gagnon MP, Curran ML, Wang W (2017) Cell-controlled hybrid
perfusion fed-batch CHO cell process provides signicant productivity improvement over
conventional fed-batch cultures. Biotechnol Bioeng 114:1438–1447. https://doi.org/10.1002/
bit.26259
34. Egan TJ, Diem D, Weldon R, Neumann T, Meyer S, Urech DM (2017) Novel multispecic heterodimeric antibody format allowing modular assembly of variable domain fragments. MAbs
9:68–84. https://doi.org/10.1080/19420862.2016.1248012
35. Chen T, Han J, Guo G, Wang Q, Wang Y, Li Y (2019) Monitoring removal of hole-hole
homodimer by analytical hydrophobic interaction chromatography in purifying a bispecic
antibody. Protein Expr Purif 164:105457. https://doi.org/10.1016/j.pep.2019.105457
36. Kuglstatter A, Stihle M, Neumann C, Muller C, Schaefer W, Klein C, Benz J, Roche
Pharmaceutical R, Early D (2017) Structural differences between glycosylated, disuldelinked heterodimeric Knob-into-Hole Fc fragment and its homodimeric Knob-Knob and HoleHole side products. Protein Eng Des Sel 30:649–656. https://doi.org/10.1093/protein/gzx041
37. Chen SW, Zhang W (2021) Current trends and challenges in the downstream purication of
bispecic antibodies. Antib Ther 4:73–88. https://doi.org/10.1093/abt/tbab007
38. Zhao DS, Gregorich ZR, Ge Y (2013) High throughput screening of disulde- containing
proteins in a complex mixture. Proteomics 13:3256–3260. https://doi.org/10.1002/
pmic.201300242
39. Makaraviciute A, Jackson CD, Millner PA, Ramanaviciene A (2016) Considerations in producing preferentially reduced half-antibody fragments. J Immunol Methods 429:50–56.
https://doi.org/10.1016/j.jim.2016.01.001
40. Goulet DR, Orcutt SJ, Zwolak A, Rispens T, Labrijn AF, de Jong RN, Atkins WM, Chiu
ML (2018) Kinetic mechanism of controlled Fab-arm exchange for the formation of bispecic immunoglobulin G1 antibodies. J Biol Chem 293:651–661. https://doi.org/10.1074/jbc.
RA117.000303
T. Iskra etal.
5 Process Development and Manufacturing Considerations for Multispecic…
41. Carlring J, De Leenheer E, Heath AW (2011) A novel redox method for rapid production of
functional bi-specic antibodies for use in early pilot studies. PLoS One 6:e22533. https://doi.
org/10.1371/journal.pone.0022533
42. Goulet DR, Zwolak A, Chiu ML, Nath A, Atkins WM (2017) Diffusion of soluble aggregates
of THIOMABs and bispecic antibodies in serum. Biochemistry 56:2251–2260. https://doi.
org/10.1021/acs.biochem.6b01097
43. Paul S, Connor J, Nesspor T, Haytko P, Boakye K, Chiu ML, Jiang H (2016) An efcient process of generating bispecic antibodies via controlled Fab-arm exchange using culture supernatants. Protein Expr Purif 121:133–140. https://doi.org/10.1016/j.pep.2016.01.014
44. O'Mara B, Gao ZH, Kuruganti M, Mallett R, Nayar G, Smith L, Meyer JD, Therriault J,
Miller C, Cisney J, Fann J (2019) Impact of depth ltration on disulde bond reduction during
downstream processing of monoclonal antibodies from CHO cell cultures. Biotechnol Bioeng
116:1669–1683. https://doi.org/10.1002/bit.26964
45. Chen W, Yang F, Wang C, Narula J, Pascua E, Ni I, Ding S, Deng X, Chu ML, Pham A, Jiang
X, Lindquist KC, Doonan PJ, Van Blarcom T, Yeung YA, Chaparro-Riggers J (2021) One size
does not t all: navigating the multi-dimensional space to optimize T-cell engaging protein
therapeutics. MAbs 13:1871171. https://doi.org/10.1080/19420862.2020.1871171
46. Moore PA, Zhang W, Rainey GJ, Burke S, Li H, Huang L, Gorlatov S, Veri MC, Aggarwal
S, Yang Y, Shah K, Jin L, Zhang S, He L, Zhang T, Ciccarone V, Koenig S, Bonvini E,
Johnson S (2011) Application of dual afnity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 117:4542–4551. https://doi.org/10.1182/
blood- 2010- 09- 306449
47. Gupta VR, Root A, Fisher T, Norberg R, David J, Clark T, Cohen J, May C, Giddabasappa A
(2020) Molecular imaging reveals biodistribution of P-cadherin LP-DART bispecic and trafcking of adoptively transferred T cells in mouse xenograft model. Oncotarget 11:1344–1357.
https://doi.org/10.18632/oncotarget.27544
131
Part IV
Process Engineering, Gene Therapy
and Vaccines
Chapter 6
Metabolic andProcess Engineering
toControl Glycan Structures
forBiopharmaceuticals Produced
inCultured Mammalian Cells
RanyaPranomphon, VijayTejwani, HussainDahodwala,
MontaropYamabhai, andSusanT.Sharfstein
Abstract Biopharmaceuticals (also known as biologics) play an increasing role in
the treatment of a wide range of diseases, particularly cancer, autoimmune diseases,
and infectious diseases. In 2017 and 2018, 11 of the 15 best-selling drugs worldwide were biopharmaceuticals, generally produced in cultured mammalian cells.
The vast majority of biopharmaceuticals are glycoproteins, in which the attached
glycan moieties play important and often critical roles in controlling activity, clearance, and immunogenicity. In addition to glycoproteins, carbohydrates, particularly
glycosaminoglycans (GAGs) such as heparin, the most widely used anticoagulant
drug in the world, are critically important biopharmaceutical products.
Many blockbuster biopharmaceuticals such as adalimumab (Humira), trastuzumab (Herceptin), and bevacizumab (Avastin) have recently come off patent,
providing an opportunity for production of biosimilar versions by companies
other than the innovator. In addition, there is increasing interest in producing
R. Pranomphon
College of Nanotechnology, Science and Engineering, University at Albany, State University
of NewYork, Albany, NY, USA
School of Biotechnology, Institute of Agricultural Technology, Suranaree University
of Technology, Nakhon Rachasima, Thailand
V. Tejwani · S. T. Sharfstein (*)
College of Nantechnology, Science and Engineering, Albany, NY, USA
e-mail: ssharfstein@albany.edu
H. Dahodwala
Institute for Bioscience and Biotechnology Research, University of Maryland,
Rockville, MD, USA
M. Yamabhai
College of Nanotechnology, Science and Engineering, State University of New York,
Albany, NY, USA
K. Gadamasetti, S. A. Kolodziej (eds.), Bioprocessing, Bioengineering
and Process Chemistry in the Biopharmaceutical Industry,
https://doi.org/10.1007/978-3-031-62007-2_6
135© The Author(s), under exclusive license to Springer Nature Switzerland AG 2024
136
R. Pranomphon etal.
glycosaminoglycans from cultured mammalian cells, rather than the current purication from animal tissues with the attendant risks of contamination by adventitious
agents and adulteration due to isolation under non-cGMP conditions. To successfully produce biosimilars and bioengineered GAGs, control of glycan composition
and structures is critical. This control is challenging as glycan synthesis is a nontemplated process, which is controlled by a complex collection of factors including
the glycoprotein being synthesized or the core protein to which the GAG is attached,
production host, enzyme activities, and bioprocess conditions.
In this chapter, we review some basics of glycoprotein and GAG biosynthesis
with a particular focus on our current understanding of how glycan structures are
controlled invivo. We then review studies in which glycan structures for recombinant proteins and glycosaminoglycans have been optimized by cell line metabolic
engineering and bioprocess manipulations. In particular, CRISPR has permitted
exquisite editing of host cells, allowing tailored production of glycan structures,
facilitating the production of biosimilars and bioengineered GAGs as well as setting
the stage for “biobetters” in which improved functionality is obtained by glycoengineering. However, complicated new products including bispecic antibodies, intricate Fc-fusion proteins and molecules not yet envisioned may necessitate new hosts
and further advances in glycoengineering.
Keywords Glycosylation · Glycoengineering · Bioprocessing · Chinese hamster
ovary cells · Monoclonal antibodies · Biosimilars
6.1 Introduction
Biological therapeutics, including monoclonal antibodies (mAbs), vaccines, hormones, and other proteins, play an increasing role in the global pharmaceutical
market, providing novel treatments for a wide range of conditions and indications.
Since 2002 there have been more than 300 biopharmaceutical approvals by the FDA
(U.S.Food and Drug Administration), and this number is continuously growing.
The vast majority of these biologics are produced in mammalian cell culture with
Chinese hamster ovary (CHO) cell lines serving as the preferred host, but other cell
lines including human embryonic kidney cells (HEK293), human retinal cells
(PERC.6), baby hamster kidney (BHK), murine myeloma (NS0) cells, and murine
(SP2/0) hybridoma cells have also been employed [1, 2]. Mammalian cells are utilized due to their ability to produce the appropriate posttranslational modications
including proper folding, glycosylation, phosphorylation, and disulde bond formation, resulting in high-quality proteins [3, 4].
Protein glycosylation is the most common posttranslational modication in
eukaryotes, formed by the attachment of glycans onto proteins [5]. Glycosylation
occurs in the endoplasmic reticulum (ER) and/or the Golgi apparatus including
6 Metabolic and Process Engineering to Control Glycan Structures…
137
N- and O-linked glycosylation, where glycan chains are added to the amide nitrogen of the asparagine residue and hydroxyl group of the serine/threonine residues,
respectively [6–8]. Glycosylation is a complex, nontemplated process, resulting
in heterogeneity in the glycan prole (microheterogeneity) and in glycan siteoccupancy (macroheterogeneity) [9, 10]. Many factors including cell type and
cell engineering, media-feed compositions, and cell culture conditions such as
temperature, pH, and dissolved oxygen and ammonia concentrations can affect
glycan patterns [1, 11, 12]. Glycosylation patterns on therapeutic glycoproteins
signicantly affect biological and physiochemical properties including efcacy,
immunogenicity, invivo half-life, protein conformation, stability, and solubility
[13–15]. Therefore, glycosylation is a critical quality attribute (CQA) of therapeutic proteins [16, 17].
In addition to glycoprotein therapeutics, there is increased interest in the recombinant or bioengineered production of carbohydrate drugs, particularly glycosaminoglycans (GAGs) such as heparin, the most widely used anticoagulant drug
worldwide [18]. GAGs are synthesized and attached to a core protein, and the structure of the GAG is controlled by an extensive biosynthetic pathway consisting of
more than 20 enzymes. Consequently, GAGs are highly heterogeneous, and their
properties are strongly inuenced by the cell line and culture conditions used for
production. The CQAs for GAGs include their sulfation pattern and for heparin, the
anticoagulant activity.
CQAs are dened as physical, chemical, biological, or microbiological properties or characteristics that must be monitored during manufacturing processes and
controlled within an appropriate limit, range, or distribution to ensure the desired
product quality and hence, the safety and efcacy of the drug products [19–21]. Due
to the natural glycan heterogeneity, there is not “one correct glycan,” though there
are certainly undesirable glycans including immunogenic forms described in Sects.
6.4 and 6.5. Moreover, the glycosylation patterns, such as degree of branching,
sialylation and fucosylation have signicant effects on biological activity as
described in Sect. 6.6.3. Consequently, glycoengineering and process engineering
may be performed to achieve a specic biological goal for the therapeutic protein.
Most critical is the need to maintain consistency throughout the product lifetime,
which may include a variety of process changes and manufacturing at many different sites.
In addition to the need to maintain quality attributes in the production of novel
therapeutics, the end of patent protection for many biotherapeutics (e.g., adalimumab (Humira), trastuzumab (Herceptin), and bevacizumab (Avastin)) provides an
opportunity for the production of biosimilars. Biosimilars are off-patent biologic
products that are highly similar but not identical to the originator biologic product
(Reference Biologic) in terms of structure, function, biological activity, immunogenicity, efcacy, and safety due to differences in manufacturing processes [22, 23].
However, in biosimilar production, it is vitally important to approximate the CQAs
of the innovator molecule to ensure efcacy. Signicant effort is often employed
during the process development of biosimilars to match the reference product
including host and cell line selection as well as optimization of bioprocess
138
conditions [24]. Furthermore, CQA identication is a key step in the quality by
design (QbD) approach to product development, a systematic approach that begins
with predened objectives and emphasizes product and process understanding and
process control, based on sound science and quality risk management. QbD has
been implemented for developing and manufacturing biologics, including biosimilars [25–27].
To understand how these steps are being implemented, this chapter provides an
overview of protein glycosylation, strategies for glycoengineering cell lines to control glycan patterns, and a discussion of the effects of process conditions on the
glycosylation prole of therapeutic protein products.
R. Pranomphon etal.
6.2 Biology ofGlycosylation
The addition of oligosaccharides onto a protein is a complex metabolic pathway,
characterized by the en-bloc transfer of polysaccharide chains, as well as the stepwise addition and removal of individual monosaccharides. The number of pathways
traversed is dependent on reaction site accessibility, the enzymatic substrate specicities, as well as spatial localization of the various enzymes and nucleotide-sugar
substrates that are necessary for the reactions to proceed in a particular order
[28, 29].
6.2.1 N-Linked Glycosylation
N-linked glycosylation initiates primarily in the ER of mammalian cells. The entire
pathway in mammalian cells involves a highly complex and interconnected reaction
network, catalyzed by glycosidases and glycosyltransferases contained within different compartments of the ER and Golgi apparatus, as depicted in the schematic in
Fig.6.1. The biosynthesis of mammalian N-glycans initiates at the cytoplasmic face
of the ER membrane with the transfer of a phosphorylated N-acetylglucosamine
(GlcNAc-P) from uridine diphosphate (UDP-GlcNAc) to the dolichol phosphate
(Dol-P) lipid carrier to generate dolichol pyrophosphate N-acetylglucosamine (DolP- P-GlcNAc) [30]. Fourteen sugars are then sequentially added to Dol-P-P-GlcNAc
to form an oligosaccharide precursor (Glc3Man9GlcNAc2) [10]. Next, oligosaccharyltransferase identies Asn-X-Ser/Thr sequons in a nascent polypeptide and
proceeds with an en-bloc transfer of Glc3Man9GlcNAc2 to the side chain amide of
asparagine, releasing Dol-P-P in the process [31]. The glucose (Glc) residues on the
precursor are sequentially trimmed by ER α-glucosidase I and II to form a monoglucosylated glycan, which is a key intermediate in the calnexin/calreticulin-associated
glycoprotein folding control cycle, an ER protein-quality assurance mechanism [32].
6 Metabolic and Process Engineering to Control Glycan Structures…
139
Fig. 6.1 An overview of glycosylation pathway in most eukaryotic cell systems. (Adapted from
[33] with permission from Springer Science+Business Media and from [1] with permission from
Oxford University Press)
Once correctly folded, the precursor is trimmed by ER α-mannosidase I to yield
Man8GlcNAc2-protein before exiting the ER. After translocation into the cisGolgi, the Man8GlcNAc2 glycoform is further trimmed by Golgi α-mannosidases I
to give Man5GlcNAc2, a key intermediate along the pathway to form hybrid and